enVVeno Medical
NVNO
20 hedge funds and large institutions have $8.35M invested in enVVeno Medical in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 3 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
0.16% less ownership
Funds ownership: 0.66% → 0.5% (-0.16%)
9% less funds holding
Funds holding: 22 → 20 (-2)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
39% less capital invested
Capital invested by funds: $13.7M → $8.35M (-$5.38M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$220K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$14.4K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.28K |
| 4 |
EE
EWG Elevate
Roseville,
California
|
+$1.83K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.02K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$940K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$51.6K |
| 3 |
Two Sigma Advisers
New York
|
-$24.4K |
| 4 |
Morgan Stanley
New York
|
-$10.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$9.75K |
NVNO Hedge Fund Activity: Q4 2022 in Review
20 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in enVVeno Medical (NVNO) for Q4 2022, worth a combined $8.35M — down 39% from $13.7M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of NVNO and 2 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 4 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $220K. The largest seller was UBS O'Connor, exiting entirely with an estimated $940K sold.
- 20 institutional investors held enVVeno Medical (NVNO) as of Q4 2022, down from 22 in Q3 2022.
- Funds reported $8.35M of enVVeno Medical stock for Q4 2022, down 39% quarter-over-quarter.
- 2 funds opened new enVVeno Medical positions in Q4 2022 and 3 closed out, a net change of -1 holder.
- The largest enVVeno Medical buyer in Q4 2022 was Susquehanna International Group, an estimated $220K added.
- The largest enVVeno Medical seller in Q4 2022 was UBS O'Connor, an estimated $940K sold.
Based on aggregated 13F filings for Q4 2022.